Format

Send to

Choose Destination
Angew Chem Int Ed Engl. 2019 Feb 18;58(8):2350-2354. doi: 10.1002/anie.201813002. Epub 2019 Jan 21.

Nucleus-Targeted Organoiridium-Albumin Conjugate for Photodynamic Cancer Therapy.

Author information

1
College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, 518060, China.
2
Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.
3
School of Pharmaceutical Science (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, China.

Abstract

An organoiridium-albumin bioconjugate (Ir1-HSA) was synthesized by reaction of a pendant maleimide ligand with human serum albumin. The phosphorescence of Ir1-HSA was enhanced significantly compared to parent complex Ir1. The long phosphorescence lifetime and high 1 O2 quantum yield of Ir1-HSA are highly favorable properties for photodynamic therapy. Ir1-HSA mainly accumulated in the nucleus of living cancer cells and showed remarkable photocytotoxicity against a range of cancer cell lines and tumor spheroids (light IC50 ; 0.8-5 μm, photo-cytotoxicity index PI=40-60), while remaining non-toxic to normal cells and normal cell spheroids, even after photo-irradiation. This nucleus-targeting organoiridium-albumin is a strong candidate photosensitizer for anticancer photodynamic therapy.

KEYWORDS:

albumin; organoiridium; photodynamic therapy; photosensitizers

PMID:
30552796
DOI:
10.1002/anie.201813002

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center